AstraZeneca is reportedly considering moving its listing to the US. Here's why AZN's expected departure is alarming for the ...

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as ...

Reports are circulating that AstraZeneca shares could be moving off the London exchange with its CEO favouring a US market ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

AstraZeneca, Britain's most valuable public company and responsible for one of the Covid vaccines, reportedly wants to move ...

AstraZeneca chief executive Sir Pascal Soriot is reportedly considering the move due to growing frustration with the UK's ...

London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca ...

Cambridge UK Pharma giant AstraZeneca is proving a variation on the proverbial enigma as it ponders the most appreciative ...

The boss of Britain’s most valuable company, Astrazeneca, has reportedly voiced his preference to move the firm’s stock ...